Ken Griffin Brainstorm Cell Therapeutics Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$0.22 - $0.42 $66 - $126	300 Added 4.17%	7,500 $1,000
Q2 2024 Aug 14, 2024	BUY	$0.34 - $0.74 $2,176 - $4,736	6,400 Added 800.0%	7,200 $2,000
Q1 2024 May 15, 2024	SELL	$0.28 - $0.66 $504 - $1,188	-1,800 Reduced 69.23%	800 $0
Q4 2023 Feb 14, 2024	SELL	$0.15 - $0.4 $11,685 - $31,160	-77,900 Reduced 96.77%	2,600 $0
Q3 2023 Nov 14, 2023	SELL	$0.2 - $2.08 $7,220 - $75,088	-36,100 Reduced 30.96%	80,500 $16,000
Q2 2023 Aug 14, 2023	SELL	$2.0 - $3.2 $11,800 - $18,880	-5,900 Reduced 4.82%	116,600 $240,000
Q1 2023 May 15, 2023	BUY	$1.43 - $3.3 $128,700 - $297,000	90,000 Added 276.92%	122,500 $404,000
Q4 2022 Feb 14, 2023	BUY	$1.37 - $4.42 $21,783 - $70,278	15,900 Added 95.78%	32,500 $53,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $4.42 $7,139 - $12,376	-2,800 Reduced 14.43%	16,600 $73,000

10.8M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $63.5M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.